Unlocking Strategies for Target Selection in Novel Conjugated Drugs
Time: 9:01 am
day: Pre-Conference Workshop Day
Details:
Selecting the right target is undeniably important for novel conjugate drugs as it plays into the efficacy, toxicity profile, and therapeutic window, ultimately determining whether this new modality is worth pursuing. Join this in-depth workshop to explore advanced strategies in target selection for the development of cutting-edge conjugated drugs, for novel targets as well as previously validated ones. Gain insights into identifying and validating optimal targets to improve efficacy, safety, and clinical outcomes.
Join this workshop to:
- Explore novel target identification for bispecific ADCs to enhance therapeutic selectivity and reduce off-target toxicity whilst getting the desired level of immune engagement
- Balance sufficient tumor cell expression without overexpression that limits penetration into large or solid tumors
- Discover the wider target space for degrader-antibody conjugates and explore the rationale behind target selection for well-matched antibody and protein of interest targets
- Develop antibody degrader conjugates with innovative approaches to selecting degradation targets, ensuring efficient and selective protein degradation
- Consider novel targets for peptide drug conjugates for improved stability, potency, as well as internalization into cells and crossing the BBB
- Address challenges in target validation and determining the most suitable biomarkers for guiding conjugated drug development
